Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: A rational approach to contraception

Blood

Volumn 118, Issue 8, 2011, Pages 2055-2061

  Van Vlijmen, Elizabeth F W ^a   Veeger, Nic J G M ^a   Middeldorp, Saskia ^b   Hamulyák, Karly ^c   Prins, Martin H ^c   Büller, Harry R ^b   Meijer, Karina ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ADOLESCENT; ADULT; CONDOM; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; ORAL CONTRACEPTION; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 80052140272     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-345678     Document Type: Review

References (39)

1. Middeldorp S, Meijers JCM, van den Ende AE, et al. Effects on coagulation of levonorgestreland desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000:84(1):4-8. (Pubitemid 30433659)
2. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestreland desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84(1):15-21. (Pubitemid 30433661)
3. Meijers JC, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two lowdose oral contraceptives. Thromb Haemost. 2000;84(1):9-14. (Pubitemid 30433660)
4. WHO Expert Group Medical eligibility criteria for contraceptive use. Reproductive Health and Research, 4th ed. Geneva, Switzerland: World Health Organization; 2009.
5. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994(8935);344:1453-1457. (Pubitemid 24351698)
6. Martinelli I, Taioli E, Buccarelli P, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 1999; 19(3):700-703. (Pubitemid 29135174)
7. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with hereditary clotting defects. Arch Int Med. 2000; 160(1):49-52. (Pubitemid 30040972)
8. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oralcontraceptives at extreme risk of venous thromboembolism? Eur J Contracept Reprod Health Care. 2000;5(2):105-112. (Pubitemid 30470061)
9. Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G2210A mutation of the prothrombin gene. Haematologica. 2001;86(9):965-971. (Pubitemid 32937706)
10. Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use. Eur Heart J. 2002;23(12):984-990. (Pubitemid 35203878)
11. Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004(1);70:3-10. (Pubitemid 38781972)
12. Vossen CY, Conard JFontcuberta Makris JM, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost. 2004; 2(9):1526-1532. (Pubitemid 40186165)
13. Brouwer JL, Veeger NJGM, Kluin-Nelemans HC, et al. Multicausal pathogenesis of venous thromboembolism. Evidence from a study in families with hereditary deficiencies of protein C, protein S, or antithrombin. Ann Int Med. 2006;145(11): 807-815.
14. van Vlijmen EFW, Brouwer JLP, Veeger NJGM, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects. Arch Int Med. 2007;167(3):282-289.
15. Folkeringa N, Brouwer JLP, Korteweg F, et al. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects. Br J Haematol. 2007;138(1):110-116. (Pubitemid 46889789)
16. Cox M, Tripp J, Blacksell S. Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002;28(2):69-72. (Pubitemid 34595934)
17. Bátár I, Sivin I. State-of-the-art of non-hormonal methods of contraception: I. Mechanical barrier contraception. Eur J Contracept Reprod Health Care,. 2010;15(2):67-88.
18. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10): 697-706.
19. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
20. Middeldorp S, Henkens CMA, Koopman MW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998;128(1):15-20. (Pubitemid 28016713)
21. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3(1):79-84. (Pubitemid 41647118)
22. Bank I, Libourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Int Med. 2004; 164(17):1932-1937. (Pubitemid 39274365)
23. Lijfering WM, Coppens M, van de Poel MHW, et al. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost. 2007;98(2):457-463. (Pubitemid 47250250)
24. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996;143(12):1257-1265. (Pubitemid 26178738)
25. Lijfering WM, Coppens M, Veeger NJ, et al. Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels. Thromb Res. 2008;123(2):244-250.
26. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64-67. (Pubitemid 24144355)
27. Danneberg J, Abbes AP, Bruggeman BJ, et al. Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin). Clin Chem. 1998;44(2):349-351. (Pubitemid 28087738)
28. Koster T, Blann AD, Briët E, et al. Role of the clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet. 1995;345(8943):152-155.
29. Rothman KJ, Greenland S. Modern Epidemiology, 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1998:247-252.
30. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167-1173. (Pubitemid 29155221)
31. Couturaud F, Kearon C, Leroyer C, et al. (Groupe d'Etude de la Thrombose de Bretagne Occidentale). Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost. 2006;96(6):744-749. (Pubitemid 44883814)
32. Martinelli I, Bucciarelli P, Margaglione M, et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol. 2000; 111(4):1223-1229. (Pubitemid 32104942)
33. Simioni P, Sanson B-J, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81(2):198-202. (Pubitemid 29078302)
34. Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic effects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632-637. (Pubitemid 351404930)
35. Martinelli I, Battaglioli T, De Stefano V, et al. The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. J Thromb Haemost. 2008;6(3):494-498. (Pubitemid 351280118)
36. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008; 359(19):2025-2033.
37. Mansour D, Inki P, Gemzel-Danielsson K. Efficacy of contraceptive methods: a review of the literature. Eur J Contr Reprod Health Care. 2010; 15(1):4-16.
38. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002;28(2):73-77. (Pubitemid 34595935)
39. Koster T, Small A, Rosendaal FR, et al. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Int Med. 1995;238(2):31-37.